Indeed, the consensus document from the European Leukemia Net minimal residual disease Working Party states that mutations in signaling pathway genes (FLT3–ITD, FLT3–TKD) most likely represent residual AML when detected but are often subclonal and have a low negative predictive value; these mutations are best used in combination with additional minimal residual disease markers [69]. The gene discussed is FLT3; the disease is acute myeloid leukemia.